5 documents

Read All
23:19 , Apr 20, 2017 |  BC Innovations  |  Product R&D

Stalling translation

Pfizer Inc. has discovered a mechanism to create small molecule inhibitors of PCSK9 by halting translation of the protein as it emerges from the ribosome. While the company is remaining tight-lipped about that program, it...
Read More
07:00 , Oct 5, 2015 |  BioCentury  |  Emerging Company Profile

Picking a PCSK9

As the first mAbs against PCSK9 are making their market debuts, several companies are vying to replace them with oral candidates. Liphorus Pharmaceuticals Inc. has assembled a test kitchen of screens for small molecules with...
Read More
07:00 , Sep 21, 2015 |  BioCentury  |  Product Development

Alnylam's lipid sync

Alnylam Pharmaceuticals Inc. and The Medicines Co. think an RNA-based approach to lowering LDL-C could help patients adhere to treatment by enabling them to receive therapy at the same time they are normally scheduled for...
Read More
08:00 , Nov 10, 2014 |  BC Week In Review  |  Company News

IRCM, Liphorus Pharmaceuticals deal

IRCM spun out Liphorus and granted the newco exclusive, worldwide rights to develop and commercialize technology targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) . The newco plans to develop small molecules against PCSK9 to treat...
Read More
03:27 , Nov 7, 2014 |  BC Extra  |  Financial News

Sanderling backs IRCM spinout Liphorus

Liphorus Pharmaceuticals Inc. (Montreal, Quebec) raised $6.4 million in a series A round from Sanderling Ventures. The startup plans to develop small molecules targeting proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) to treat hypercholesterolemia....
Read More